Product Name :
PD 166326
Description:
IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor. Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. They have been shown not only to be critical regulators of normal cellular processes but also to have a key role in the development of many types of cancer. In vitro: PD 166326 was identified as a pyridopyrimidine-type inhibitor of receptor tyrosine kinases inhibiting c-abl and Bcr/Abl-dependent cell growth. In addition, PD 166326 could also potently inhibit c-src. Moreover, PD166326 was found to be superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, such as the src family member Lyn [1, 2]. In vivo: In mice with the CML-like disease, PD166326 could rapidly inhibit Bcr/Abl kinase activity after a single po dose and showed great antileukemic activity. It was found that 70% of PD166326-treated mice achieved a white blood cell count less than 20.0 × 109/L at necropsy, compared with 8% of imatinib mesylate–treated animals. Furthermore, 2/3 of PD166326-treated mice had complete resolution of splenomegaly, compared with none of the imatinib mesylate–treated animals. In addition, PD166326 could also prolong the survival of mice with imatinib mesylate–resistant CML induced by the Bcr/Abl mutants of P210/H396P and P210/M351T . Clinical trial: So far, no clinical study has been conducted.
CAS:
185039-91-2
Molecular Weight:
427.28
Formula:
C21H16Cl2N4O2
Chemical Name:
6-(2,6-dichlorophenyl)-2-{[3-(hydroxymethyl)phenyl]amino}-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one
Smiles :
CN1C(=O)C(=CC2C=NC(NC3=CC(CO)=CC=C3)=NC1=2)C1C(Cl)=CC=CC=1Cl
InChiKey:
ZIQFYVPVJZEOFS-UHFFFAOYSA-N
InChi :
InChI=1S/C21H16Cl2N4O2/c1-27-19-13(9-15(20(27)29)18-16(22)6-3-7-17(18)23)10-24-21(26-19)25-14-5-2-4-12(8-14)11-28/h2-10,28H,11H2,1H3,(H,24,25,26)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Remogliflozin etabonate} site|{Remogliflozin etabonate} Membrane Transporter/Ion Channel|{Remogliflozin etabonate} Biological Activity|{Remogliflozin etabonate} Description|{Remogliflozin etabonate} supplier|{Remogliflozin etabonate} Epigenetic Reader Domain}
Shelf Life:
≥12 months if stored properly.{{Bazedoxifene} medchemexpress|{Bazedoxifene} Vitamin D Related/Nuclear Receptor|{Bazedoxifene} Technical Information|{Bazedoxifene} Description|{Bazedoxifene} supplier|{Bazedoxifene} Cancer}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:23319057
Additional information:
IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor. Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones. They have been shown not only to be critical regulators of normal cellular processes but also to have a key role in the development of many types of cancer. In vitro: PD 166326 was identified as a pyridopyrimidine-type inhibitor of receptor tyrosine kinases inhibiting c-abl and Bcr/Abl-dependent cell growth. In addition, PD 166326 could also potently inhibit c-src. Moreover, PD166326 was found to be superior to imatinib mesylate in inhibiting the constitutive tyrosine phosphorylation of numerous leukemia-cell proteins, such as the src family member Lyn [1, 2]. In vivo: In mice with the CML-like disease, PD166326 could rapidly inhibit Bcr/Abl kinase activity after a single po dose and showed great antileukemic activity. It was found that 70% of PD166326-treated mice achieved a white blood cell count less than 20.0 × 109/L at necropsy, compared with 8% of imatinib mesylate–treated animals. Furthermore, 2/3 of PD166326-treated mice had complete resolution of splenomegaly, compared with none of the imatinib mesylate–treated animals. In addition, PD166326 could also prolong the survival of mice with imatinib mesylate–resistant CML induced by the Bcr/Abl mutants of P210/H396P and P210/M351T . Clinical trial: So far, no clinical study has been conducted.|Product information|CAS Number: 185039-91-2|Molecular Weight: 427.28|Formula: C21H16Cl2N4O2|Chemical Name: 6-(2,6-dichlorophenyl)-2-{[3-(hydroxymethyl)phenyl]amino}-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one|Smiles: CN1C(=O)C(=CC2C=NC(NC3=CC(CO)=CC=C3)=NC1=2)C1C(Cl)=CC=CC=1Cl|InChiKey: ZIQFYVPVJZEOFS-UHFFFAOYSA-N|InChi: InChI=1S/C21H16Cl2N4O2/c1-27-19-13(9-15(20(27)29)18-16(22)6-3-7-17(18)23)10-24-21(26-19)25-14-5-2-4-12(8-14)11-28/h2-10,28H,11H2,1H3,(H,24,25,26)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|